• Deal Opens Pathway for Analyte Development
  • Alastair Smith

News & Views

Deal Opens Pathway for Analyte Development

Mar 18 2021

Cancer therapies and diagnostics developer Avacta Group plc has signed an agreement with Biokit, a Werfen Company, to incorporate its Affimer reagents into an in-vitro diagnostic (IVD) product for detection of a key analyte of interest.

Under the licence, Biokit has the right to develop, manufacture and commercialise through original equipment manufacturer (OEM) partners, an in-vitro diagnostic (IVD) immunoassay for this analyte. Avacta will receive royalties on future sales of any products brought to market following completion of product development and regulatory approvals.

Details of the agreement were not disclosed.

Dr Marta Palicio, Innovation Director of Biokit commented: "Biokit is very pleased to have reached this agreement with Avacta. The agreement will increase the competitiveness of our customised assay offering for our partners. Avacta’s technology also enables us to innovate our assays with new reagents like Affimer reagents, an alternative to antibodies. We can now move onto the next stage of development, incorporation of this technology into new products. We hope this is the first of many assays containing Affimer reagents which will be developed by Avacta.”


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

MEDICA 2024

Nov 11 2024 Dusseldorf, Germany

FILTECH

Nov 12 2024 Cologne, Germany

Intech

Nov 12 2024 Tel Aviv, Israel

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

View all events